Dynavax Technologies (NASDAQ:DVAX) shares traded during most recent session to reach at the closing price of $11.19. The stock exchanged hands on average of 963.5 Million shares, yielding a market cap of $726.45 Million. Wall Street analysts covering the stock are projecting that the stock will reach $29.33 within the next 52-weeks. The mean target projections are based on 6 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Dynavax Technologies (NASDAQ:DVAX) high price target of $38 and with a conservative view have low price target of $23.
JP Morgan “Upgrades” Dynavax Technologies (NASDAQ:DVAX) in a research note issued to investors on 5/10/18 to Overweight with price target of $.
Additionally on 2/14/18 JP Morgan “Maintained” Dynavax Technologies (NASDAQ:DVAX) to Neutral setting price target at $25 and on 2/14/18 JP Morgan “Downgrades” the stock to Neutral at $. Furthermore on 11/10/17 Cantor Fitzgerald “Maintained” the stock to Overweight at $25.
On the other hand the company has Relative Strength Index (RSI 14) of 39.45 along with Average True Range (ATR 14) of 0.72, Consequently Dynavax Technologies (NASDAQ:DVAX)’s weekly and monthly volatility is 8.20%, 5.71% respectively. The company’s beta value is at 0.35.
In terms of Buy, Sell or Hold recommendations, Dynavax Technologies (NASDAQ:DVAX) has analysts’ mean recommendation of 1.8. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Dynavax Technologies (NASDAQ:DVAX)’s minimum EPS for the current quarter is at $-0.6 and can go high up to $-0.56. The consensus mean EPS for the current quarter is at $-0.57 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.38 earnings per share for the same quarter during last year.
Previously Dynavax Technologies (NASDAQ:DVAX) reported $-0.63 earnings per share (EPS) for the quarter, meeting the consensus estimate of $-0.63 by $0. The company posted an earnings surprise of 0%.
Dynavax Technologies (NASDAQ:DVAX)’s revenue estimates for the current quarter are $3.75 Million according to 6 number of analysts, for the current quarter the company has high revenue estimates of $6.7 Million in contradiction of low revenue estimates of $2.26 Million. For the current year the company’s revenue estimates are $12.99 Million compared to low analyst estimates of $7.07 Million and high estimates of $24.62 Million according to 6 number of analysts.
Currently Dynavax Technologies (NASDAQ:DVAX)’s shares owned by insiders are 0.7%, whereas shares owned by institutional owners are 80.6%. However the six-month change in the insider ownership was recorded -0.87%, as well as three-month change in the institutional ownership was recorded 0%.
Dynavax Technologies (NASDAQ:DVAX)’s trailing twelve month revenues are $1.5 Million, whereas its price to sales ratio for the same period is 484.3. Its book value per share for the most recent quarter is $2.11 while its price to book ratio for the same period is 5.3, as for as the company’s cash per share for the most recent quarter is $3.33, however its price to cash per share ratio for the same period is 3.36. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.